The Food and Drug Administration approved daraxonrasib last month for advanced pancreatic cancer, doubling median overall survival to 13.2 months in clinical trials. While researchers praised the breakthrough for a historically difficult disease, patients immediately faced hurdles with expanded access closures and commercial insurance denials.
FDA Approval and Clinical Trial Results for Daraxonrasib
The Food and Drug Administration approved a new drug for advanced pancreatic cancer last month, marking a major milestone against one of the deadliest forms of the disease. In the global phase 3 clinical trial known as RASolute 302, the medication doubled survival time for patients with previously treated metastatic pancreatic cancer. The trial recorded a median overall survival of 13.2 months, compared to 6.7 months for patients who received the chemotherapy standard of care.
According to the National Cancer Institute, more than 67,000 people will receive a pancreatic cancer diagnosis in the United States in 2026, with nearly 57,000 projected to die from it. The five-year survival rate stands at 13.7 percent. Brian Wolpin, a professor of medicine at Harvard Medical School and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute, led the international trial and presented the results in May at the annual meeting of the American Society of Clinical Oncology.
“This study provided the combination of results that we were hoping for, with longer length of life and better quality of life for daraxonrasib compared to chemotherapy.”
The medication, developed by California-based Revolution Medicines, targets and inhibits a mutated enzyme called KRAS that drives pancreatic cancer cell growth. RAS proteins were long considered undruggable because of their smooth surfaces. Scientists overcame that barrier through foundational discoveries originating from the laboratory of Harvard chemist Gregory Verdine. Taken as a once-daily pill, the drug spares patients from lengthy infusion room visits, central access ports, and the harsher side effects associated with standard chemotherapy.
Rasonque Approval Closes Early Access Program for Patients
Regulatory approvals typically expand patient access to new therapies, but the clearance of Revolution Medicines’ drug brought immediate complications for families relying on early access programs. When the treatment received FDA approval under the brand name Rasonque, the manufacturer immediately closed its expanded access program. That sudden shutdown left patients in limbo who were in the middle of paperwork or awaiting approval to secure the medication.
While early access programs close upon federal approval, commercial insurance coverage and Medicare Part D plans often require weeks or months to establish billing codes and review processes. That administrative lag creates a dangerous window for patients fighting aggressive diseases like pancreatic cancer.
Arturo Loaiza-Bonilla, a hematologist-oncologist at St. Luke’s University Health Network in Pennsylvania and co-founder of cancer technology company Massive Bio, encountered a Medicare denial for a patient shortly after the approval. The insurer’s denial letter stated that the medication is not properly listed with the Food and Drug Administration and does not meet Part D eligibility requirements. After the physician posted a screenshot of the letter to social media, the pharmacy benefit manager OptumRx contacted his office to approve the prior authorization and confirm coverage. Other patients at the network, however, awaited responses from their insurers.
Impact on Patients Facing Advanced Metastatic Disease
For patients and their families, the administrative delay translates to agonizing uncertainty. Kelsey Solano, a critical care nurse from Washington state, watched the approval bring some true hope while simultaneously closing off the compassionate use pathway she needed for her husband, Juan.
Juan Solano was diagnosed with stage 3 pancreatic cancer in January 2025. After undergoing a complex Appleby Procedure and completing a frontline chemotherapy regimen of FOLFIRINOX, the couple believed he was disease-free by November 2025. Within two months, the cancer returned as stage 4, spreading to his liver, bile duct, and peritoneum. A subsequent clinical trial at the Fred Hutchinson Cancer Center slowed the disease temporarily before tumors progressed.
As Juan rolled off the trial, his clinical status shifted rapidly, prompting his medical team to pursue Rasonque through the manufacturer’s early access program. The sudden program closure left the family scrambling to meet clinical requirements and secure commercial coverage while his condition continued to change.
Keep reading